Psilocybin Therapy for Depression: Faster and More Durable Than SSRIs?

Traditional antidepressants present significant limitations, often requiring daily oral consumption and weeks to months of treatment before potential efficacy can be determined. These medications are also associated with difficult withdrawal effects when patients attempt to discontinue use. Conversely, emerging clinical data on psilocybin treatment for treatment-resistant depression shows a potential for faster therapeutic outcomes and increased durability, with improvements observed lasting up to six months following only one or two sessions. This represents a significant shift from existing therapeutic protocols, where intensive, recurring treatments like ketamine or Spravato pose substantial challenges for patient adherence and long-term integration into daily routines.